-+ 0.00%
-+ 0.00%
-+ 0.00%

European Commission approves Roche’s Susvimo® for the treatment of neovascular age-related macular degeneration (nAMD)

Barchart·09/21/2026 10:45:00
Listen to the news

Basel, 21 September 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the European Commission has approved Susvimo® (ranibizumab 100 mg/mL solution for injection) for the treatment of neovascular age-related macular degeneration (nAMD), a leading cause of vision loss in people over the age of 60.5,6 

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.